Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03615742

Diesel Exhaust Induces Glucocorticoid Resistance

The investigators are studying the effects of exposure to diesel exhaust on lung inflammation in the presence and absence of an inhaled corticosteroid. Although data is mixed, studies show that asthmatics have increased lung inflammation and worse symptoms during periods of higher air pollution despite taking their anti-inflammatory corticosteroid medication. One possible reason is that air pollution exposure may decrease the ability of corticosteroids to combat inflammation.

To test this volunteers will inhale either a placebo or a corticosteroid, before sitting in an exposure booth for 2 hours breathing either filtered air or diluted diesel exhaust. Samples will be collected before and after exposure to analyze the effects of budesonide and diesel exhaust exposure.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year–49 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of British Columbia

Vancouver, British Columbia, V5Z1M9, Canada

Location status: Recruiting

Location contact

Chris Carlsten, MD MPH

CONTACT

[email protected]

604-875-4729

Christopher F Rider, PhD

SUB_INVESTIGATOR

Robert Newton, PhD

SUB_INVESTIGATOR

Ryan D Huff, MSc

CONTACT

[email protected]

604-875-5132

About this study

  • Purpose Inhalation of air pollutants leads to both airway inflammation, with increased cytokine expression and inflammatory cell recruitment to the airways, and to airway hyperresponsiveness, which together contribute to airway resistance and breathing difficulties. Correlational data indicate that exposure to air pollution increases inhaled corticosteroids (ICS) use in asthmatics, suggesting that steroidal anti-inflammatory medications are suboptimally effective under these conditions. However, a major issue is that no study has yet been performed specifically to determine the effects of controlled diesel exhaust (DE) exposure on responses to ICS. Furthermore, investigators need better insight into mechanisms, including the effects of epigenetic modifications and polymorphisms in oxidative stress response genes, which remain under explored. Investigators anticipate that an improved understanding of air pollution-induced ICS hyporesponsiveness (reduced effectiveness) could underpin preventative guidelines, guide ICS usage in response to environmental exposures, and inform rational pharmaceutical development. Ultimately this could lead to fewer exacerbations in asthmatic and other susceptible populations.

Hypothesis:

Acute exposure to DE reduces ICS-inducible gene expression in vivo in asthmatics, in part through effects on epigenetic processes.

Justification:

Air pollution exposure correlates with increased use of ICS inhalers in asthmatics, suggesting that ICS offer less control during periods of higher air pollution. As genes induced by ICS are critical in reducing inflammatory messenger ribonucleic acid (mRNA) and protein expression, the investigators have chosen to focus on the effects of DE on ICS-inducible gene expression as our primary endpoint.

Research Method:

To test this the effects of air pollution exposure on a corticosteroid, volunteers will inhale either a placebo (inhaler containing no medication) or budesonide (1.6mg), before sitting in our exposure booth for 2 hours breathing either filtered air (as a control) or diluted diesel exhaust (standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less).

Volunteers will visit our lab four different times to be exposed to: 1) placebo & filtered air, 2) placebo & diesel exhaust, 3) corticosteroid and filtered air, and 4) corticosteroid and diesel exhaust. Investigators can then compare responses to each of these combinations of exposures.

Investigators will take blood samples before and after volunteers complete each of these exposures to track how they affect the body. Six hours after placebo or budesonide inhalation a research bronchoscopy will be performed during which a very thin flexible tube will be inserted through the mouth and down into lungs to collect samples from each volunteer.

Bronchoalveolar lavage, bronchial washes, bronchial brushes and tissue biopsies will be obtained for analysis of gene expression and epigenetic endpoints. Nasal lavage samples will also be collected to examine responses in the upper airways and blood and urine will be studied to examine systemic responses. Spirometry will be used to assess effects on airway function.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 19-49
  • Have physician-diagnosed asthma confirmed by the study physician examination, spirometry, methacholine challenge provocative concentration causing a 20% fall (PC20) of <16 mg/mL, and questionnaires during a screening visit

Exclusion criteria

  • Smoking of any kind (0.5 pack-years ever, or any current) or use of vape/vaporizing devices
  • Regular anti-histamine, NSAID, corticosteroid or other controller medication use
  • Pregnancy or breastfeeding
  • Methacholine PC20 >16
  • Relevant cardiac condition or arrhythmia
  • Body mass index of >35
  • Currently participating in another study that may interfere with this study
  • Use of either inhaled or oral corticosteroids in preceding 6 months
  • Substantial comorbidities on study physician's examination or other concerns
  • Surgery scheduled before anticipated study completion

Treatment and study plan

Placebo

Other

Inhalation of air through a Turbuhaler that contains no medication, as a control.

Budesonide

Drug

1.6mg of budesonide from a Turbuhaler.

Other names: Pulmicort

Filtered Air

Other

Exposure to HEPA filtered air, as a control.

Diesel Exhaust

Other

Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).

Other names: Traffic Related Air Pollution

Primary outcomes

  1. Change in DNA methylation, mRNA and protein expression attributable to diesel exhaust and inhaled corticosteroid

    Time frame: Baseline versus 6 hours

    EPIC arrays and RNA Seq will be used to determine effect of exposure(s)

Secondary outcomes

  1. Modification by variants in genes governing inflammation and responses to oxidative stress after DE exposure and ICS.

    Time frame: Baseline versus 6 hours

    Genotypes will be assessed using Applied Biosystems Axiom Precision Medicine Research arrays, with validation by polymerase chain reaction assay (PCR). The data generated will be used to generate a gene score (single value for each participant) which will be used for statistical interaction analysis.

Study contacts

Contact information is provided by the study sponsor or research team.

Agnes CY Yuen, BSc

CONTACT

[email protected]

6048754111 ext. 66455

Parteek (PJ) Johal, BCS

CONTACT

[email protected]

6048755132

Sponsors and collaborators

Lead sponsor

University of British Columbia

Other

Collaborators

  • AllerGen NCE Inc.
  • Canadian Institutes of Health Research (CIHR)

Registry information

Acronym: DIGR

Important dates

Study start
2018
Primary completion
2025
Study completion
2025
First posted
Aug 6, 2018
Registry last updated
Jul 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.